ArticleThe Journal of pediatrics2026
Characteristics of Transient Elastography for Hepatic Steatosis and Fibrosis in Children Undergoing Liver Biopsy.
Article in The Journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo determine the diagnostic performance of vibration-controlled transient elastography (VCTE) measured the same day as liver biopsy in screening and risk stratification of steatosis and fibrosis in children and adolescents. STUDY
designWe compared VCTE measures of hepatic steatosis and fibrosis with liver biopsy histology as the reference standard. Sequential patients undergoing liver biopsy in a hospital-based pediatric gastroenterology practice were included. In primary analyses, we determined area under the receiver operating characteristic (AUC), sensitivity, and specificity for VCTE-derived measures of steatosis and fibrosis. In post hoc subgroup analyses, we examined VCTE measures of steatosis and fibrosis among patients according to metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis.
resultsAmong 145 children, with mean age 13.6 years (SD: 5.1 years), VCTE measures of any steatosis (≥5%) showed AUC 0.89 (95% CI 0.83-0.94), sensitivity 0.90 (95% CI 0.79-0.97), and specificity 0.74 (95% CI 0.64-0.83). VCTE measures for fibrosis stage F2 or greater had AUC 0.71 (0.59-0.82), sensitivity 0.75 (0.53-0.90), and specificity 0.63 (0.54-0.72). In post hoc subgroup analyses among the subgroup of 37 patients with MASLD, VCTE had low ability to detect greater grades of steatosis (AUC 0.61 for S2 or greater) and low ability to detect clinically meaningful fibrosis (AUC 0.56 for F2 or greater).
conclusionsIn the overall cohort, VCTE measurements on the same day as liver biopsy showed moderate ability to detect steatosis and limited ability to detect F2 fibrosis. Diagnostic discrimination for steatosis and fibrosis was low among the subgroup with MASLD. Disease-specific studies, rather than heterogeneous cohorts of mixed disease types, are needed to advance clinical implementation of noninvasive steatosis and fibrosis measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.